Chimeric antigen receptor T reg therapy in transplantation.

Autor: Eskandari SK; Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: s.eskandari@umcg.nl., Daccache A; Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Bioscience Education and Research (UFR Biosciences), Claude Bernard University Lyon 1, Lyon, France., Azzi JR; Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jazzi@bwh.harvard.edu.
Jazyk: angličtina
Zdroj: Trends in immunology [Trends Immunol] 2024 Jan; Vol. 45 (1), pp. 48-61. Date of Electronic Publication: 2023 Dec 19.
DOI: 10.1016/j.it.2023.11.005
Abstrakt: In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (T reg ) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR T regs and how they may address important drawbacks of polyclonal T regs and conventional immunosuppressants. We examine a growing body of preclinical findings of CAR T reg therapy in transplantation, discuss CAR T reg design specifics, and explore established and attractive new targets in transplantation. In addition, we explore present impediments where future studies will be necessary to determine the efficacy of CAR T regs in reshaping alloimmune responses and transplant microenvironments to reduce reliance on chemical immunosuppressants. Overall, ongoing studies and trials are crucial for understanding the full scope of CAR T reg therapy in transplantation.
Competing Interests: Declaration of interests The authors declare no conflicts of interests.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: